NEW YORK, Sept. 5, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Lifecore and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On August 22, 2023, Lifecore issued a press release disclosing receipt of "a notice ('Notice') on August 17, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market ('Nasdaq') stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the 'Listing Rule') because the Company failed to timely file its Annual Report on Form 10-K for the period ended May 28, 2023 (the 'Form 10-K') with the Securities and Exchange Commission."
On this news, Lifecore's stock price fell $0.45 per share, or 5%, to close at $8.55 per share on August 23, 2023.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980
SOURCE Pomerantz LLP
![](https://rt.prnewswire.com/rt.gif?NewsItemId=DC01038&Transmission_Id=202309051755PR_NEWS_USPR_____DC01038&DateId=20230905)
Share this article